Yoo Jin Joo

Abstract Introduction: The selective prostacyclin (IP) receptor agonist selexipag is FDA-approved for the treatment of pulmonary arterial hypertension. Selexipag also has anti-inflammatory effects in peripheral tissues, but the ability of selexipag to modulate central neuroinflammation has not been comprehensively examined. Therefore, this study investigated the effect of selexipag on LPS-mediated neuroinflammatory responses in vitro and in vivo.

Abstract Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L-DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail.

Molecular Brain, Aug 2023 Alzheimer’s disease (AD) is a neurodegenerative disease characterized by Aβ deposition, tauopathy, neuroinflammation, and impaired cognition. The recent identification of associations between protein kinases and AD pathology has spurred interest in tyrosine kinase inhibitors (TKIs) as potential strategic therapeutic agents for AD.